Matthew Shawn Morris Sells 7,788 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 7,788 shares of Privia Health Group stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $24.99, for a total value of $194,622.12. Following the transaction, the director directly owned 68,188 shares of the company’s stock, valued at approximately $1,704,018.12. This represents a 10.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Matthew Shawn Morris also recently made the following trade(s):

• On Friday, February 27th, Matthew Shawn Morris sold 16,550 shares of Privia Health Group stock. The stock was sold at an average price of $25.00, for a total value of $413,750.00.
• On Friday, December 12th, Matthew Shawn Morris sold 13,647 shares of Privia Health Group stock. The shares were sold at an average price of $25.01, for a total value of $341,311.47.

Privia Health Group Stock Performance

NASDAQ PRVA traded up $0.29 during trading hours on Monday, reaching $24.04. The company’s stock had a trading volume of 1,472,614 shares, compared to its average volume of 813,700. The company’s 50-day moving average is $23.07 and its two-hundred day moving average is $23.50. The stock has a market cap of $2.96 billion, a PE ratio of 141.41, a PEG ratio of 1.59 and a beta of 0.82. Privia Health Group, Inc. has a fifty-two week low of $18.77 and a fifty-two week high of $26.51.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.21. The firm had revenue of $541.17 million during the quarter, compared to the consensus estimate of $516.61 million. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The company’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.21 EPS. Equities analysts expect that Privia Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

Institutional Trading of Privia Health Group

A number of hedge funds have recently modified their holdings of PRVA. Great Lakes Advisors LLC purchased a new position in shares of Privia Health Group during the third quarter valued at $4,487,000. Advantage Alpha Capital Partners LP acquired a new position in shares of Privia Health Group in the second quarter worth $3,941,000. Hsbc Holdings PLC raised its holdings in shares of Privia Health Group by 69.2% during the second quarter. Hsbc Holdings PLC now owns 113,718 shares of the company’s stock worth $2,549,000 after acquiring an additional 46,526 shares in the last quarter. Edgestream Partners L.P. purchased a new stake in shares of Privia Health Group during the second quarter worth $2,209,000. Finally, Bailard Inc. purchased a new position in Privia Health Group in the second quarter valued at about $531,000. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on PRVA shares. Stephens reiterated an “overweight” rating and issued a $32.00 price target on shares of Privia Health Group in a report on Thursday, December 4th. Barclays lifted their price target on Privia Health Group from $22.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. Truist Financial upped their target price on Privia Health Group from $31.00 to $33.00 and gave the company a “buy” rating in a report on Monday. Canaccord Genuity Group increased their price target on Privia Health Group from $34.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday. Finally, JPMorgan Chase & Co. raised their price objective on shares of Privia Health Group from $32.00 to $33.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.93.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.